Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma - PubMed
5 hours ago
- #large B-cell lymphoma
- #glofitamab
- #real-world evidence
- The study evaluated real-world outcomes of fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma (LBCL).
- It focused on complete responders to assess the durability of response and survival benefits after treatment.
- Findings suggest that fixed-duration glofitamab can lead to sustained complete responses in this high-risk patient population.
- The research underscores the potential of glofitamab as an effective therapeutic option for relapsed/refractory LBCL.